Protein Helps Cells Duplicate Correctly, Avoid Becoming Cancer
Posted on: Monday, 5 October 2009, 14:20 CDT
A Purdue University researcher has discovered that the absence of certain proteins needed for proper cell duplication can lead to cancer.
Xiaoqi Liu, an assistant professor of biochemistry, found that cytoplasmic linker protein-170, or CLIP-170, plays a major role in proper cell duplication and DNA distribution. When the protein is removed, cell duplicates lack entire copies of DNA and can become cancerous. Liu's findings were published in the early online version of the Journal of Biological Chemistry.
"DNA has to be equally distributed from a mother cell to its daughter cells. If the cells are not identical to the mother cell, they become cancer," Liu said. "Normal cells have a very tightly regulated process to avoid aneuploidy, or the unequal distribution of chromosomes. Aneuploidy is a hallmark of cancer."
A cell will go through two important processes before it divides: It will create a second copy of its own DNA, and it will create two centrosomes, or poles, that will act as magnets to draw the DNA to themselves. When the centrosomes have attracted the DNA, the cell divides in a process called mitosis, creating two identical cells.
But when CLIP-170 was removed from a cell in Liu's lab, more than two centrosomes formed, pulling only two copies of the DNA in several directions. Each centrosome received less than a full copy of the DNA.
"If there are multiple poles, the cell becomes confused and becomes cancerous or transformed," Liu said.
Liu also found that a cyclin-dependent kinase called Cdc2, activates CLIP-170 in cells by attaching a phosphate group to the protein. Cdc2 is an enzyme that is considered the master regulator of cell growth, and without it, CLIP-170 does not do its job and multiple centrosomes form.
"Without either of these, a cell has an increased chance of becoming a cancer cell," Liu said.
The National Institutes of Health funded Liu's research. Liu will continue to look for regulators and mechanisms that turn normal cells into cancer cells
Writer: Brian Wallheimer, Purdue University
---
On the Net:
Related Articles
- FDA approves GlaxoSmithKline's VOTRIENT(TM) for advanced renal cell cancer
- Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
- Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
- ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer
- Integral Molecular Launches Lipoparticles for Cell-Free Analysis of Membrane Proteins
- ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined With Nexavar(R)
- Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors
- ZymoGenetics Begins Phase 1/2 Clinical Trial With IL-21 and Nexavar in Patients With Renal Cell Cancer
- New In Vitro Study of GlycoGenesys' GCS-100LE Yields Promising Data in Chronic Lymphocytic Leukemia and Other B-Cell Cancers
 |
 |
User Comments (0)
RSS Feeds